China Tightens Control On New Pharmaceutical Entrants

China's State FDA has announced it will tighten the admittance criteria of pharmaceutical companies and products, while at the same time encourage enterprises to merge for better competitiveness. Currently, an industry with an excessive number of players has given rise to unhealthy competition, allowing opportunistic counterfeiters to slip in unsafe low-quality drugs and drive up prices. In the last one-and-a-half years, the government cancelled 27 drug and medical device production licenses, withdrew 157 drug GMP certificates, and ordered 370 manufacturers to suspend production until rectification was carried out. SFDA is joining forces with the department of development and reform to set up policies for large-scale pharmaceutical production to ensure product quality and safety. (Click here for more - Chinese Language)